Analystreport

Akari Therapeutics PLC (NASDAQ: AKTX) had its "neutral" rating re-affirmed by analysts at Chardan Capital.

Akari Therapeutics Plc - American Depositary Shares  (AKTX) 
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations